Nimbus Therapeutics harnesses the power of computational chemistry to design breakthroughs for the treatment of substantial and underserved human diseases. The company's focus on metabolic diseases, cancer and immune-inflammatory disorders is driven by its selection of well validated targets that have proven intractable to the approaches taken by others in the pharmaceutical and biotechnology industry. Using its unique approach and technological capabilities, Nimbus is rapidly progressing highly selective and potent small molecules through discovery and development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/18/15 | $43,000,000 | Series B |
Atlas Venture Bill Gates Lightstone Ventures Lilly Ventures Pfizer Strategic Investments Group SR One | undisclosed |
| 06/05/18 | $65,000,000 | Venture |
Atlas Venture Bill Gates Lightstone Ventures Lilly Ventures Pfizer Venture Investments Schrodinger, Inc SR One | undisclosed |
| 10/15/20 | $60,000,000 |
BVF Partners RA Capital Management | undisclosed | |
| 07/15/21 | $105,000,000 |
Access Biotechnology Atlas Venture BVF Partners  Commodore Capital Logos Capital RA Capital Management Surveyor Capital | undisclosed | |
| 09/12/22 | $125,000,000 |
Access Biotechnology Atlas Venture Bain Capital Life Sciences Bill Gates BVF Partners Lightstone Ventures Pfizer Venture Investments RA Capital Management SR One SV Health Investors | undisclosed | |
| 09/18/23 | $210,000,000 |
Atlas Venture Bain Capital Life Sciences BVF Partners Gates Frontier GV Lightstone Ventures Pfizer Venture Investments RA Capital Management SR One SV Health Investors | undisclosed |
